NASDAQ · Healthcare · Biotechnology
Insight Molecular Diagnostics Inc.
IMDX
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. CEO Joshua Riggs · Market cap $142.0M.
$5.29
+0.31 · +6.22%
52w hi $8.5152w lo $2.33
Off 52w high 54.9%
57
ROUTINE
Current InsiderScore
Corp · 90d
6
6 buys · 0 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
1
0 strong · 1 notable
Analyst consensus
Strong Buy
Avg PT $10.50
Section 01
Recent Form 4 filings
7 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Apr 27 | BROADWOOD PARTNERS, L.P. | Buy | 250,923 | $3.64 | +$913K | 57 | |
| Apr 24 | BROADWOOD PARTNERS, L.P. | Buy | 38,880 | $3.53 | +$137K | 54 | |
| Apr 23 | BROADWOOD PARTNERS, L.P. | Buy | 280,381 | $3.50 | +$982K | 57 | |
| Apr 20 | BROADWOOD PARTNERS, L.P. | Buy | 40,690 | $3.88 | +$158K | 54 | |
| Apr 17 | BROADWOOD PARTNERS, L.P. | Buy | 40,114 | $3.57 | +$143K | 54 | |
| Apr 16 | BROADWOOD PARTNERS, L.P. | Buy | 102,057 | $3.45 | +$352K | 54 | |
| Feb 10 | BROADWOOD PARTNERS, L.P. | Buy | 521,739 | $5.75 | +$3.00M | 60 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
JunJulAugSepOctNovDecJanFebMarAprMay